Morningside
VC Fund
Shanghai, China
Morningside is a VC fund in Shanghai focused on Health Care and Biotechnology. Morningside makes venture capital investments in companies with novel science and technology. We are characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically.Based in the greater Boston area, our team of entrepreneurial investment professionals has deep experience in life sciences, digital health,AI, materials and technology.Founded in 1986 as a family office for the Chan family, charitable commitments to education, research and healthcare include the Harvard T.H. Chan School of Public Health, the UMass Chan Medical School, and the MIT Morningside Academy for Design.
- Total investments:
- 143
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Morningside invests in
Stages Morningside invests in
Countries Morningside invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $6M–$45M
- Series B
- $14M–$80M
- Venture - Series Unknown
- $3M–$75M
Investment Focus
Industry
- Health Care 56 (39%)
- Biotechnology 53 (37%)
- Medical 27 (19%)
- Therapeutics 21 (15%)
- Pharmaceutical 19 (13%)
Stage
- Series A 39 (27%)
- Series B 33 (23%)
- Venture - Series Unknown 24 (17%)
- Series C 13 (9%)
- Seed 9 (6%)
Country
- United States 81 (57%)
- United Kingdom 14 (10%)
- China 12 (8%)
- Canada 2 (1%)
- France 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anthony Aiudi
Investment Professional
|
Investment Professional | Total investments: 6 | Find email | |
Mick Sawka
Investment Manager
|
Investment Manager | Total investments: 18 | Find email | |
Gerald Chan
Co-Founder, Investment Director & Board Member
|
Co-Founder, Investment Director & Board Member | Total investments: 1 | Find email | |
Justin Burns
Investment Professional
|
Investment Professional | Total investments: 2 | Find email | |
|
Michael Xue
Managing Director
|
Managing Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Xealth is a platform for digital health that enables health systems to easily organize, integrate, deploy and activate digital health tools from within the EHR workflow. Through the secure Xealth platform, clinicians can find and order the right digital tools and programs for patients direct from the EHR workflow, send these digital health ordersto the patient’s smartphone or desktop, and then monitor patient engagement and analyze the effects of more engaged patients. Xealth enables healthcare teams to order digital content and services as easily as they do medications today. The patients can then access these digital health prescriptions from the provider's portal so that they can actively manage their health. It spun out of Providence St. Joseph Health (PSJH) in 2017, and investors include McKesson Ventures, Novartis, Philips, and ResMed as well as Providence Ventures, UPMC, and the Froedtert and Medical College of Wisconsin Health Network. | Venture - Series Unknown / Mar 25, 2025 | ||
| SimpliFed is a healthcare technology company that provides virtual maternal care focused on breastfeeding and baby feeding support for families. It offers a telehealth platform that connects parents with certified lactation and baby-feeding specialists, delivering personalized, evidence-based care from pregnancy through the postpartum period. Theplatform includes services such as feeding guidance, remote monitoring, mental health screenings, and ongoing support to improve maternal and infant health outcomes. SimpliFed works closely with healthcare providers and health plans, integrating its services into existing care systems to enhance access and continuity of care. Its approach emphasizes inclusive, judgment-free support, helping parents make informed decisions about feeding methods while addressing both physical and emotional well-being. | $4M / Seed / Feb 04, 2025 | ||
| AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $112M / Series C / Feb 03, 2025 | ||
| Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M / Series C / Jan 08, 2025 | ||
| Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases. | $181.4M / Series D / Nov 12, 2024 | ||
| CairnSurgical is developing innovative patient-specific tools to guide surgical interventions for patients with cancer. | $4.5M / Series A / Aug 21, 2024 | ||
Xencore Network
|
Xencore Network manufactures and sells a wide range of network chipsets. | Series C / May 11, 2024 | |
| ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials. | $42.6M / Series C / Jan 03, 2024 | ||
| FireCyte Therapeutics is developing treatment for microglia and neuroinflammation in progressive neurodegenerative eye diseases. | Venture - Series Unknown / Jan 01, 2024 | ||
| At Suvera we superpower primary care to deliver truly effective virtual care for patients with long-term conditions. Effective for us means improved outcomes for patients - less hospital admissions, less doctor appointments, more time in good health. | Venture - Series Unknown / Jan 01, 2024 | ||
| See all 143 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Morningside invest in?
Morningside invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 143 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Morningside's check size?
Morningside typically joins rounds of $6M–$45M at Series A, $14M–$80M at Series B and $3M–$75M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Morningside participates in.
How do I contact Morningside?
Public channels for Morningside include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Morningside?
The team at Morningside includes Anthony Aiudi (Investment Professional), Mick Sawka (Investment Manager) and Gerald Chan (Co-Founder, Investment Director & Board Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
